共 50 条
- [41] INTRIGUE: A phase III, randomized,open-label study to evaluate the efficacy and safety of ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinibJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (36)Heinrich, Michael C.Jones, Robin LewisGelderblom, HansGeorge, SuzanneSchoffski, Patrickvon Mehren, Margaret
- [42] ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma: Five year follow-up.JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Neoptolemos, John P.Palmer, Daniel H.Ghaneh, PaulaValle, Juan W.Cunningham, DavidWadsley, JonathanMeyer, TimAnthoney, AlanGlimelius, BengtFalk, StephenSegersvard, RalfMiddleton, Gary WilliamRoss, Paul J.Wasan, Harpreet SinghMcDonald, AlecCrosby, Tom David LewisPsarelli, Eftychia EiriniHammel, PascalHackert, ThiloBuchler, Markus W.
- [43] Abraxane plus cisplatin compared with gemcitabine plus cisplatin as first- line treatment in patients with metastatic triple-negative breast cancer (GAP): A multicenter, randomized, open-label, phase III trialANNALS OF ONCOLOGY, 2020, 31 : S354 - S354Hu, X.Wang, B.Zhang, J.Wang, Z.Sun, T.Wang, S.Teng, Y.Yan, M.Wang, X.Jiang, Z.Cai, L.Pan, Y.
- [44] A phase II, open-label, randomized clinical trial of panitumumab plus gemcitabine and oxaliplatin (GEMOX) versus GEMOX alone as first-line treatment in advanced biliary tract cancer: The Vecti-BIL study.JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)Leone, FrancescoMarino, DonatellaFilippi, RobertoCereda, StefanoBelli, CarmenSpadi, RosellaNasti, GuglielmoMontano, MassimoAmatu, AlessioAprile, GiuseppeCagnazzo, CelesteFasola, GianpieroSiena, SalvatoreCiuffreda, LiberoReni, MicheleAglietta, Massimo
- [45] A randomized, double-blind, multicenter phase II AIO trial with gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with chemotherapy-naive advanced or metastatic biliary tract cancer: First safety and efficacy data.JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)Moehler, M. H.Schimanski, C. C.Kanzler, S.Woerns, M. A.Denzer, U.Kolligs, F. T.Ebert, M. P.Distelrath, A.Geissler, M.Zeuzem, S.Lammert, F.Lohse, A. W.Dollinger, M. M.Lindig, U.Duerr, E. M.Lubomierski, N.Zimmermann, S.Kabisch, M.Schadmann-Fischer, S.Galle, P. R.
- [46] A randomised controlled trial of gemcitabine hydrochloride plus S-1 combination therapy versus gemcitabine hydrochloride therapy alone in pancreatic cancer patients aged >= 75 years: a study protocol for an open-label randomised feasibility studyBMJ OPEN GASTROENTEROLOGY, 2018, 5 (01):Ishii, HiroshiYamashita, NatsumiUeno, MakotoOhkawa, ShinichiSaito, Akiko M.Sekimoto, Mitsugu
- [47] Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: A prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)Qin, ShukuiBai, YuxianWang, ZishuChen, ZhendongXu, RuihuaXu, JianmingZhang, HongmeiChen, JiaYuan, YingLiu, TianshuYang, LinZhong, HaijunChen, DonghuiShen, LinHao, ChunyiFu, DeliangCheng, YingYang, JianweiBai, Xian HongLi, Jin
- [48] Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trialLANCET ONCOLOGY, 2015, 16 (07): : 763 - 774Thatcher, NickHirsch, Fred R.Luft, Alexander V.Szczesna, AleksandroCiuleanu, Tudor E.Dediu, MirceaRamlau, RodrygGaliulin, Rinat K.Balint, BeatrixLosonczy, GyoergyKazarnowicz, AndrzejPark, KeunchilSchumann, ChristianReck, MartinDepenbrock, HenrikNanda, ShivaniLetunic, Anamarija KruljacKurek, RaffaclPaz-Ares, LuisSocinskf, Mark A.
- [49] NeoOPTIMIZE: An open-label, phase II trial and biomarker discovery platform to assess the efficacy of adaptive switching of modified FOLFIRINOX (mFFX) or gemcitabine/nab-paclitaxel (GA) as a neoadjuvant strategy for patients with resectable/borderline resectable and locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC)JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)Lopez, Charles D.Kardosh, AdelChen, Emerson Yu-shengMayo, Skye C.Eil, RobertWorth, Patrick JosephGilbert, Erin W.Rocha, Flavio G.Nabavizadeh, NimaGrossberg, AaronGuimaraes, AlexanderFoster, BryanBrinkerhoff, BrianGoodyear, ShaunTaber, ErinKeith, DoveBrody, Jonathan RobertMills, Gordon B.Sears, RosalieSheppard, Brett C.
- [50] Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Javle, Milind M.Borbath, IvanClarke, Stephen JohnHitre, ErikaLouvet, ChristopheMercade, Teresa MacarullaOh, Do-YounSpratlin, Jennifer L.Valle, Juan W.Weiss, Karl HeinzBerman, CraigHowland, MichaelYe, YiningCho, TerryMoran, SusanAbou-Alfa, Ghassan K.